Bastian von Tresckow

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 967 citations · Full text

Surgical Oncology, Immunology, Pathology +18

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 492 citations · Full text

Lymphoid Neoplasia, Hematology, Immunology +6

Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells

Elke Pogge von Strandmann, Venkateswara R. Simhadri, Bastian von Tresckow et al. · Immunity · 2007 · 337 citations · Full text

Natural Killer Cells, Cancer Immunosurveillance, Immunology +9

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 326 citations · Full text

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Bastian von Tresckow, Annette Plütschow, Michael Fuchs et al. · Journal of Clinical Oncology · 2012 · 311 citations · Full text